Dasatinib induced pleural effusions - Reply.
作者信息
Aj Abdulla Mohammad, Yassin Mohamed A
机构信息
.
Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar.
出版信息
Acta Biomed. 2020 Mar 19;91(1):144-145. doi: 10.23750/abm.v91i1.9263.
Abstract
摘要
相似文献
1
Dasatinib induced pleural effusions - Reply.达沙替尼引起的胸腔积液——回复
Acta Biomed. 2020 Mar 19;91(1):144-145. doi: 10.23750/abm.v91i1.9263.
2
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.伊马替尼治疗失败后使用达沙替尼治疗的慢性髓性白血病患者的胸腔积液
J Clin Oncol. 2007 Sep 1;25(25):3908-14. doi: 10.1200/JCO.2007.12.0329.
3
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.未选择的老年慢性髓性白血病患者在接受达沙替尼治疗期间胸腔积液的发生率、风险因素和处理。
Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19.
4
Dasatinib-induced pleural effusions: a lymphatic network disorder?达沙替尼诱导的胸腔积液：一种淋巴管网络紊乱？
Am J Med Sci. 2009 Nov;338(5):414-7. doi: 10.1097/MAJ.0b013e3181ae9227.
5
Pleural effusions due to dasatinib.达沙替尼引起的胸腔积液。
Curr Opin Pulm Med. 2010 Jul;16(4):351-6. doi: 10.1097/MCP.0b013e328338c486.
6
Pleural Effusion in Dasatinib-Treated Patients With Chronic Myeloid Leukemia in Chronic Phase: Identification and Management.达沙替尼治疗的慢性期慢性髓性白血病患者的胸腔积液：识别与管理
Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):78-82. doi: 10.1016/j.clml.2016.09.012. Epub 2016 Sep 17.
7
Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.达沙替尼治疗期间的胸腔/心包积液：发生率、处理方法以及与积液发生相关的风险因素。
Expert Opin Drug Saf. 2010 Sep;9(5):713-21. doi: 10.1517/14740331003742935.
8
[A case report of refractory pleural effusion associated with dasatinib in the treatment of chronic myeloied leukemia].
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Apr;23(2):401-6. doi: 10.7534/j.issn.1009-2137.2015.02.020.
9
Dasatinib induced pleuro-pericardial effusion.达沙替尼诱发了胸膜心包积液。
Acta Biomed. 2020 Mar 19;91(1):142-143. doi: 10.23750/abm.v91i1.8914.
10
[Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].达沙替尼治疗伊马替尼耐药的BCR/ABL阳性白血病的疗效
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Jun;21(3):581-6. doi: 10.7534/j.issn.1009-2137.2013.03.009.
本文引用的文献
1
An uncommon case of chronic myeloid leukemia with variant cytogenetic.一例罕见的伴有细胞遗传学变异的慢性髓性白血病。
Acta Biomed. 2018 Apr 3;89(3-S):28-32. doi: 10.23750/abm.v89i3-S.7217.
2
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.未选择的老年慢性髓性白血病患者在接受达沙替尼治疗期间胸腔积液的发生率、风险因素和处理。
Hematol Oncol. 2013 Jun;31(2):103-9. doi: 10.1002/hon.2020. Epub 2012 Jul 19.
3
Pleural effusions due to dasatinib.达沙替尼引起的胸腔积液。
Curr Opin Pulm Med. 2010 Jul;16(4):351-6. doi: 10.1097/MCP.0b013e328338c486.
4
Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.达沙替尼 100 毫克，每日一次，可最大程度减少慢性期慢性髓性白血病患者胸腔积液的发生，并且对发生胸腔积液的患者的疗效没有影响。
Cancer. 2010 Jan 15;116(2):377-86. doi: 10.1002/cncr.24734.
5
Dasatinib-induced pleural effusions: a lymphatic network disorder?达沙替尼诱导的胸腔积液：一种淋巴管网络紊乱？
Am J Med Sci. 2009 Nov;338(5):414-7. doi: 10.1097/MAJ.0b013e3181ae9227.
6
Dasatinib in chronic myelogenous leukemia.达沙替尼用于慢性粒细胞白血病
N Engl J Med. 2006 Sep 7;355(10):1062; author reply 1063-4. doi: 10.1056/NEJMc061882.
Zotero 插件